News & Updates

Show Multimedia Only

Inebilizumab reduces flare risk in IgG4-RD patients across demographics

30 Jul 2025 by

Treatment with inebilizumab reduced the risk of disease flares in patients with immunoglobulin G4-related disease (IgG4-RD) irrespective of sex, age, or race, according to a subgroup analysis of the phase III MITIGATE study presented at EULAR 2025.

Inebilizumab reduces flare risk in IgG4-RD patients across demographics

30 Jul 2025

Sarilumab helps improve patient-reported outcomes in relapsing polymyalgia rheumatica

24 Jul 2025

In the treatment of patients with relapsing polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper, the use of sarilumab appears to produce clinically important improvements in health-related quality of life and patient-reported outcomes, according to the results of a phase III study.

Sarilumab helps improve patient-reported outcomes in relapsing polymyalgia rheumatica

24 Jul 2025

Apremilast trims fat mass, reducing CV events in PsA

23 Jul 2025

Treatment with apremilast results in fat mass reduction among patients with psoriatic arthritis (PsA), indicating positive cardiovascular (CV) and metabolic effects, which may lower the risk of CV events, a recent study has shown.

Apremilast trims fat mass, reducing CV events in PsA

23 Jul 2025

Delays, higher costs in tocilizumab therapy add to burden of GCA

23 Jul 2025

Significant delays occur in the initiation of tocilizumab (TCZ) therapy among patients with giant cell arteritis (GCA), reports a US study.

Delays, higher costs in tocilizumab therapy add to burden of GCA

23 Jul 2025

Fatigue, sleep disturbance hound patients with PMR

22 Jul 2025

In addition to the pain and stiffness that polymyalgia rheumatic (PMR) brings, patients are also burdened by persistent fatigue and sleep disturbance, reveals a study.

Fatigue, sleep disturbance hound patients with PMR

22 Jul 2025

Novel CD40L inhibitor excels in reaching lupus goal of care

19 Jul 2025 by

Adding the novel CD40L inhibitor dapirolizumab pegol (DZP) to standard of care appears to help patients with systemic lupus erythematosus (SLE) achieve low disease activity and remission, according to a prespecified secondary outcome analysis of the phase III PHOENYCS GO trial.

Novel CD40L inhibitor excels in reaching lupus goal of care

19 Jul 2025

GLP-1 RAs show signal of benefit in fibromyalgia

18 Jul 2025 by

New research suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly used for diabetes and obesity, may hold therapeutic potential for patients with fibromyalgia.

GLP-1 RAs show signal of benefit in fibromyalgia

18 Jul 2025

RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

16 Jul 2025 by

A 12-month therapeutic intervention with self-administered abatacept can delay the onset of rheumatoid arthritis (RA) in at-risk individuals for up to 4 years, according to results from the ALTO follow-up study presented at EULAR 2025.

RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

16 Jul 2025

Nerandomilast safe, effective in autoimmune disease-related PPF

11 Jul 2025 by

Treatment with nerandomilast demonstrates efficacy in slowing forced vital capacity (FVC) decline in patients with autoimmune interstitial lung disease (ILD) similar to that seen in the overall trial population, reveals a subgroup analysis of the FIBRONEER-ILD study.

Nerandomilast safe, effective in autoimmune disease-related PPF

11 Jul 2025

Deucravacitinib delivers superior efficacy, safety in active PsA

10 Jul 2025 by

Deucravacitinib exhibits superiority over placebo in terms of overall disease activity measures, musculoskeletal and dermatologic manifestations, and quality of life in adults with active psoriatic arthritis (PsA) who are naïve to biologic disease-modifying antirheumatic drugs (DMARDs), according to the results of the POETYK PsA-1 study.

Deucravacitinib delivers superior efficacy, safety in active PsA

10 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

Inebilizumab reduces flare risk in IgG4-RD patients across demographics

Inebilizumab reduces flare risk in IgG4-RD patients across demographics

Sarilumab helps improve patient-reported outcomes in relapsing polymyalgia rheumatica

Sarilumab helps improve patient-reported outcomes in relapsing polymyalgia rheumatica

Apremilast trims fat mass, reducing CV events in PsA

Apremilast trims fat mass, reducing CV events in PsA

Delays, higher costs in tocilizumab therapy add to burden of GCA

Delays, higher costs in tocilizumab therapy add to burden of GCA

Fatigue, sleep disturbance hound patients with PMR

Fatigue, sleep disturbance hound patients with PMR

Novel CD40L inhibitor excels in reaching lupus goal of care

Novel CD40L inhibitor excels in reaching lupus goal of care

GLP-1 RAs show signal of benefit in fibromyalgia

GLP-1 RAs show signal of benefit in fibromyalgia

RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

Nerandomilast safe, effective in autoimmune disease-related PPF

Nerandomilast safe, effective in autoimmune disease-related PPF

Deucravacitinib delivers superior efficacy, safety in active PsA

Deucravacitinib delivers superior efficacy, safety in active PsA